Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib

2 juli 2019 uppdaterad av: AHS Cancer Control Alberta

Evaluation of Technetium-99m Sestamibi to Determine Muscle Energy Metabolism in RCC (Renal Cell Cancer) Patients Treated With Sunitinib

Sunitinib is a chemotherapy approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC). Fatigue is a very common side effect of sunitinib that frequently causes dose reductions. The cause of this fatigue remains unclear. This study will use a special type of scan to study sunitinib-induced fatigue in relation to exercise.

Studieöversikt

Status

Indragen

Detaljerad beskrivning

Sunitinib, a type of tyrosine kinase inhibitor (TKI) has been approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC). Fatigue is a very common side effect of sunitinib that frequently causes dose reductions. The cause of this fatigue remains unclear. It has been shown that TKIs disrupt growth factor pathways in muscles leading to muscle shrinkage. If sunitinib associated fatigue is due to altered muscle physiology at a molecular level, there will be observable changes in the uptake of 99mTc-sestamibi in scintigraphy scans. The study objective is to determine if sunitinib-induced fatigue as determined by VO2 and QOL fatigue related questionnaire responses are correlated to molecular changes in the muscles as evidenced by 99mTc-sestamibi uptake.

Studietyp

Observationell

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • Cross Cancer Institute

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Men and women aged 18 years of age or older with a confirmed diagnosis of renal cell carcinoma. Participants will receive standard of care treatment with sunitinib. Participants must be willing to undergo exercise testing and diagnostic imaging with technitium 99m-sestamibi

Beskrivning

Inclusion Criteria:

  1. Signed informed consent before any study procedures completed
  2. Patients must have histologically or cytologically confirmed RCC.
  3. Four weeks must have elapsed since prior chemotherapy, hormonal therapy, targeted therapy or radiation therapy. There is no restriction on the amount of bone marrow previously radiated.
  4. Recovery to baseline or, at most, grade 1 of all drug-related toxicities due to prior chemotherapy, radiation, hormonal therapy, or molecular targeted therapy, expect for alopecia.
  5. Male / female subject ≥ 18 years of age
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of <2 (Karnofsky >70%)
  7. Life expectancy of at least 12 weeks
  8. Normal organ and marrow function as defined by :

    • absolute neutrophil count (ANC) > 1500/mcL
    • hemoglobin (Hb) > 90 g/L
    • platelet count ≥ 1000.000/mcL,
    • total bilirubin ≤ 1.5 x the upper limit of normal range (ULN)
    • alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (<5 x ULN presence of liver metastases)
    • creatinine < 1.5 x institutional ULN
  9. Cardiac ejection fraction by MUGA scan or echocardiogram must be >50% for patients at baseline.
  10. Ability to understand the purpose of the study and the willingness to sign a written informed consent document
  11. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Standard Nuclear Medicine department pregnancy screening will be conducted prior to each 99mTc-sestamibi scan. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. The investigator is requested to advise the patient how to achieve an adequate contraception.
  12. Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

  1. Patients who have had chemotherapy, hormonal therapy, molecular targeted therapy, or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  2. Patients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents.
  3. Prior treatment with a drug with known anti-angiogenic properties, including other tyrosine kinase inhibitors to VEGFR
  4. Any psychological, familial, sociological, or geographical conditions that do not permit medical follow-up and compliance with the study protocol.
  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, HIV, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  6. Patients that are on therapeutic dose of coumadin or an INR of 1.5 c ULN. Patients that are on low dose coumadin (2mg or less for patency of the central venous catheter) or therapeutic dose of low molecular weight heparin will be allowed.
  7. Patients who cannot swallow
  8. Patients who are breast-feeding.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
99mTc-sestamibi uptake in muscle cells
Tidsram: 12 weeks from start of treatment
12 weeks from start of treatment
99mTc-sestamibi uptake in muscle cells
Tidsram: 24 weeks from start of treatment
24 weeks from start of treatment
99mTc-sestamibi uptake in muscle cells
Tidsram: 36 weeks from start of treatment
36 weeks from start of treatment

Sekundära resultatmått

Resultatmått
Tidsram
Incidence of sunitinib related fatigue
Tidsram: 36 weeks after the start of sunitinib treatment
36 weeks after the start of sunitinib treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Michael Sawyer, MD, Alberta Health services

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 juni 2015

Primärt slutförande (Faktisk)

18 mars 2019

Avslutad studie (Faktisk)

18 mars 2019

Studieregistreringsdatum

Först inskickad

21 april 2015

Först inskickad som uppfyllde QC-kriterierna

23 april 2015

Första postat (Uppskatta)

28 april 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 juli 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 juli 2019

Senast verifierad

1 juli 2019

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera